Lantus is for use in adults with type 1 or type 2 diabetes, and in children at least 6 years old withtype 1 diabetes. For type 1 diabetes, Lantus is used together with a short-acting insulin given before meals. Some brands of insulin glargine are for use only in adults. Carefully follo...
BASAGLAR® is a long-acting basal insulin used to control high blood sugar in adults and pediatric populations with type 1 diabetes and adults with type 2 diabetes
Insulin glargine (100 units/mL; Basaglar or Lantus): Treatment of type 1 diabetes mellitus in adults and children ≥6 years of age or type 2 diabetes mellitus in adults who require long-acting insulin for control of hyperglycemia.Insulin glargine (300 units/mL; Toujeo): Treatment of type ...
In the DEVOTE safety outcomes study, Tresiba® U-100 demonstrated no increased risk of major adverse cardiovascular events (MACE) vs Lantus (insulin glargine) U-100 for adults with T2D and ASCVD.5,a The secondary confirmatory endpoint in the DEVOTE study demonstrated significantly lower rates of...
DEVOTE: a landmark safety outcomes trial for Tresiba® U-1001 The landmark DEVOTE study compared Tresiba® U-100 vs insulin glargine U-100 in adults with T2D and ASCVD.1,2 Results | Study design In patients with T2D and ASCVD DEVOTE is the first safety ...
Gla = glargine; HDL-C = high density lipoproteins-cholesterol; HLC = hepatic lipid content; HTGC = hepatic triglyceride content; iEGP = insulin-stimulated suppression of endogenous glucose production; LDL-C = low density lipoprotein-cholesterol; IHLC = intrahepatic ...
Lilly insulin glargine (LY IGlar; Basaglar®) and the reference insulin glargine product (IGlar; Lantus®) are basal insulin glargine analogs with identical amino acid sequence and similar pharmacological profiles. ELEMENT 5, a Phase 3, prospective, randomized, multinational, two-arm, active-...
Initial insulin glargine doses were similar among all weight groups: median (range) 0.299 (0.227-0.4), 0.297 (0.204-0.421), and 0.291 (0.194-0.394) units/kg/dose, respectively, for the underweight, normal weight, overweight/obese groups. No significant differences in discharge fasting glucose ...
SOLIQUA 100/33 is an injectable prescription medicine that contains 2 diabetes medicines, insulin glargine and lixisenatide, which may improve blood sugar (glucose) control in adults with type 2 diabetes when used with diet and exercise. It has not been studied in people with a history of pancre...
a Stable doses of metformin (metformin ≥1000 mg/day and no more than the maximum approved dose per country-specific label) and/or a sulfonylurea for 2 months prior to Visit 1, and during the screening/lead-in Period. b The initial dose of insulin glargine was 6 IU/day for patients...